Case Report on Docetaxel-Induced Interstitial Lung Disease

Abstract

Docetaxel belongs to taxane family of antineoplastic agents that are indicated for the treatment of locally advanced or metastatic non-small-cell lung cancer. Docetaxel is associated with many adverse effects, and pulmonary reaction has an incidence of 41%. However, interstitial pulmonary disease is found to occur only in <1% of the population as per the post-marketing surveillance reports. Here, we report a case of docetaxel-induced interstitial lung disease (ILD). The patient information and details were collected using the hospital information system. The adverse drug reaction (ADR) of ILD occurred after 5 cycles of chemotherapy with docetaxel at a dose of 60 mg/m 2 that is 80 mg IV. The causality of the event in our case was assessed using the Naranjo ADR probability scale which marked a score of 7 (probable). It is necessary that all physicians be aware of the reaction and to closely monitor clinicoradiological and functional status of the patients at regular intervals after administration of docetaxel.

Docetaxel induced subacute interstitial lung disease in a patient with prostate cancer

“…However, the weekly schedule of docetaxel reported lower incidence of myelosuppression than the tri weekly schedule. 11 This also shows that incidence of ILD due to docetaxel is more related to delivery schedule rather than its dose. Docetaxel is a non-ionic surfactant belonging to the family of polysorbate 80.…”